Berlin, Germany

Wolf-Hagen Schunck

USPTO Granted Patents = 5 

 

 

Average Co-Inventor Count = 6.6

ph-index = 2

Forward Citations = 6(Granted Patents)


Company Filing History:


Years Active: 2016-2025

Loading Chart...
Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: Innovations of Wolf-Hagen Schunck: A Pioneer in Eicosanoid Research

Introduction

Wolf-Hagen Schunck, based in Berlin, Germany, is an influential inventor known for his significant contributions to the field of medicinal chemistry. With a total of five patents, his work primarily revolves around the development of novel compounds that address critical health issues related to neovascularization and inflammation.

Latest Patents

Among his latest innovations, Schunck has developed analogs of CYP-eicosanoids designed for treating or preventing disorders associated with neovascularization and inflammation. This invention focuses on compounds that are robust analogues of bioactive lipid mediators derived from omega-3 polyunsaturated fatty acids (n-3 PUFAs). These compounds aim to treat or reduce the risk of developing inflammatory disorders, particularly those related to ophthalmic conditions. Furthermore, Schunck has introduced eicosanoid derivatives that modulate conditions associated with cardiac damage, especially cardiac arrhythmias.

Career Highlights

Wolf-Hagen Schunck has had a distinguished career, contributing to prestigious institutions such as the University of Texas System and Max-Dellbrueck-Centrum für Molekulare Medizin. His impressive expertise in the field has enabled him to explore innovative therapies, significantly impacting the understanding and treatment of various medical conditions.

Collaborations

Throughout his career, Schunck has collaborated with notable figures in the scientific community, including Robert Fischer and Gerd Wallukat. These partnerships have fostered a rich environment for innovation and the advancement of research in eicosanoid-related therapies.

Conclusion

In summary, Wolf-Hagen Schunck's groundbreaking work in developing eicosanoid analogs highlights his dedication to improving healthcare outcomes. His innovative patents serve as a testament to his commitment to addressing pressing health challenges through scientific discovery and collaboration.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…